SCHOTT Expands U.S. Ops After Successful Year

Plans another record investment of $450 million to fuel growth and meet demand in top performing areas including SCHOTT’s pharmaceutical solutions

SCHOTT, a specialty glass and international technology group, grew sales in the U.S. by 11% in 2021 to more than $530.6 million. In 2021, SCHOTT also increased its number of employees in the U.S. by nearly 100 and increased investments by almost $3 million.

“We adjusted our strategy to focus on the U.S. and activities in markets where we anticipate long-term growth. We have already recognized gains from that pivot and are well positioned to have an even better year in 2022,” said Bill James, Vice President of R&D and New Ventures at SCHOTT North America. “Our optimized presence in the U.S. will bring greater innovation and add to the sterling reputation that SCHOTT has built for generations.”

Top performing areas included SCHOTT’s pharmaceutical solutions as it played an integral role in supporting COVID-19 efforts. This year, SCHOTT plans another record investment of $450 million to fuel growth and meet demand.

 The following are pharmaceutical related highlights from 2021 and future plans for SCHOTT in the U.S.:

Lebanon, PA

•Pharmaceutical systems business unit increased manufacturing capacity to help SCHOTT produce vials for 5 billion doses of COVID-19 vaccines

•Multimillion-dollar capital investments tripling its capacity for pre-sterilized, ready-to-use glass vials, as well as various facility upgrades.

Phoenix, AZ

•New manufacturing facility added via acquisition of Applied Microarrays Inc. (AMI), serving the diagnostics market with point-of-care, microfluidic devices, and other consumables

•New production hub will open in spring 2022 to cater to the fast-growing and dynamic diagnostics market.